Business Wire - July 2, 2004
"This is a major victory for Retractable Technologies, Inc. and healthcare workers in the U. S. and around the world," said Thomas J. Shaw, President and CEO. "In our view, the substantial amount of this settlement vindicates our allegations that BD has blocked our life-saving technology from being used in American and overseas medical facilities, thereby endangering the lives of thousands of healthcare workers who have suffered accidental needlestick injuries, and millions more patients who have contracted deadly diseases such as HIV/AIDS and hepatitis C through needle reuse. Such injuries are preventable using Retractable's VanishPoint(R) safety needle devices." Accidental needlestick injuries and the reuse of conventional disposable syringes are widely regarded as being major causes of transmission of HIV/AIDS and other blood-borne diseases, especially in the developing world.
Shaw added, "While we are confident we would have prevailed at trial, we decided to settle because any resulting verdict and judgment would have been subject to the delays associated with an appeal. With this settlement behind us, we will be in a strong position to market our products to customers in the U. S. and overseas by stressing the superior safety, reliability, and cost-effectiveness of our products."
As part of the settlement with BD, each company released the other from causes of action based on conduct up to the settlement date. In May 2003, Retractable settled with the other three original defendants in the federal antitrust case for cash and other consideration. Those defendants were Novation and Premier Inc., the two largest hospital group purchasing organizations (GPOs), and Tyco International, the second largest U. S. needle device manufacturer.
Retractable Technologies, Inc. manufactures and markets VanishPoint(R) automated retraction safety syringes and blood collection devices, which virtually eliminate health care worker exposure to accidental needlestick injuries. These revolutionary devices use a patented friction ring mechanism that causes the contaminated needle to retract automatically from the patient into the barrel of the device, a feature that is designed to prevent reuse. VanishPoint(R) safety needle devices are distributed by various specialty and general line distributors. For more information on Retractable, visit our Web site at www.vanishpoint.com.
Forward-looking statements in this press release are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 and reflect the Company's current views with respect to future events. The Company believes that the expectations reflected in such forward-looking statements are accurate. However, the Company cannot assure you that such expectations will materialize. The Company's actual future performance could differ materially from such statements. Factors that could cause or contribute to such differences include, but are not limited to: the impact of dramatic increases in demand; the Company's ability to quickly increase its production capacity in the event of a dramatic increase in demand; and the Company's ability to access the market; the Company's ability to continue to finance research and development as well as operations and expansion of production through equity and debt financing; the increased interest of other syringe marketers in providing safety needle devices to their customers; and other risks and uncertainties that are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
CONTACT: Retractable Technologies, Inc.
Investor Contact
Douglas W. Cowan, 888-806-2626 or 972-294-1010
rtifinancial@vanishpoint.com
or
Media Contact
Phillip L. Zweig, 508-627-3285 or 212-490-0811
plzweig@aol.com
SOURCE: Retractable Technologies, Inc.
040702
BW040702
Copyright © 2004 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .